Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 4:16 AM
Ignite Modification Date:
2025-12-25 @ 4:16 AM
NCT ID:
NCT02193620
Brief Summary:
The purpose of this study is to assess the effectiveness, safety and pharmacokinetics of Oral Nalbuphine in the treatment of postoperative pain following hemorrhoidectomy.
Detailed Description:
• Primary Efficacy Endpoint: Pain assessment calculated as the area under the curve of VAS pain intensity scores through 48 hours.
• Secondary Efficacy Endpoints:
1. Consumption of diclofenac (Day 1-2) via Intramuscular Injection (IM injection).
2. Time from the end of operation to the first IM injection diclofenac dose
3. Brief Pain Inventory (BPI).
4. Patient satisfaction.
Study:
NCT02193620
Study Brief:
Protocol Section:
NCT02193620